A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease (DUET ENCORE-CD)
A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Crohn Disease
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 460
- Started
- 22 May 2026
- Main results due (estimated)
- 12 June 2028
- Study ends (estimated)
- 12 July 2030
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- Double (participant, investigator)
- Sites
- 287 · 8 in India
- First posted
- 11 May 2026
- Registry updated
- 3 November 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion criteria: * Have a diagnosis of Crohn's disease (CD) or fistulizing CD established greater than or equal to (\>=) 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD * Have moderately to severely active CD based on crohn's disease activity index (CDAI) criteria defined as a baseline CDAI score \>= 220 but less than or equal to (\<=) 450 and either: a. Mean daily stool frequency (SF) count \>= 4.0, based on the unweighted CDAI component of the number of liquid or very soft stools or b. Mean daily AP score \>= 2.0, based on the unweighted CDAI component of abdominal pain (AP) * Have moderately to severely active ileal and/or colonic CD as assessed by central review of the screening video ileocolonoscopy based on simple endoscopic score for crohn's disease (SES-CD) criteria * Have had an inadequate initial response, loss of response, or intolerance to previously approved systemic therapies Exclusion criteria: * Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, ulcerative colitis (UC) or clinical findings highly suggestive of UC * Complications of CD such as symptomatic bowel strictures or stenoses, or any other manifestation that may require intestinal surgery while enrolled in the study * Presence of draining (that is, functioning) stoma or ostomy * Has a history of short bowel syndrome, is missing greater than (\>) 2 of the 5 ileocolonic segments, or has any other medical condition that could preclude or confound the ability to use efficacy assessment tools (such as CDAI) to assess response to study intervention * Currently has or is suspected of having an abscess
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).
What participants receive
- Experimental
JNJ-78934804
Participants will receive JNJ-78934804 induction dose, at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.
Drug: JNJ-78934804
- Active comparator
Guselkumab
Participants will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the LTE phase.
Drug: JNJ-78934804 · Drug: Guselkumab
Interventions
JNJ-78934804Drug
Also known as JNJ-4804
JNJ-78934804 will be administered subcutaneously.
GuselkumabDrug
Also known as TREMFYA
Guselkumab will be administered subcutaneously.
What the study measures
Primary outcomes
Co-Primary: Percentage of Participants with Clinical Remission at Week 48
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than (\<) 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame: At Week 48
Co-Primary: Percentage of Participants with Endoscopic Remission at Week 48
Endoscopic remission is defined as a Simple Endoscopic Score for Crohn's Disease (SES-CD) score of less than or equal to (\<=) 4 with at least a 2-point reduction from baseline and no subscore greater than (\>) 1 in any individual component. The SES-CD is based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Time frame: At Week 48
Secondary outcomes
Percentage of Participants with Deep Remission at Week 48
Deep remission (composite endpoint) is defined as achieving both clinical remission and endoscopic remission at Week 48 at the participant level. Clinical remission is defined as a CDAI score of \<150 and Endoscopic remission is defined as a SES-CD score of \<= 4 with at least a 2-point reduction from baseline and no subscore \>1 in any individual component. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Time frame: At Week 48
Percentage of Participants with Corticosteroid-Free (90-Day) Clinical Remission at Week 48
Corticosteroid-free (90-day) clinical remission at Week 48 is defined as clinical remission at Week 48 and not receiving corticosteroids for at least 90 days prior to Week 48. Clinical remission is defined as a CDAI score of \<150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame: At Week 48
Percentage of Participants with Corticosteroid-Free (90-day) PRO-2 Remission at Week 48
Corticosteroid-free (90-day) patient-reported outcome(s) (PRO-2) remission at Week 48 is defined as an abdominal plan (AP) mean daily score less than or equal to (\<=) 1 and stool frequency (SF) mean daily score \<= 2.8, and no worsening of AP or SF from baseline, and not receiving corticosteroids for at least 90 days prior to Week 48.
Time frame: At Week 48
Percentage of Participants with Sustained Clinical Remission
Sustained clinical remission is defined as clinical remission at Week 12 and Week 48. Clinical remission is defined as CDAI score of \<150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame: At Weeks 12 and 48
Percentage of Participants with Histologic-Endoscopic Remission at Week 48
Composite endpoint defined as achieving both histologic remission (defined as a Robarts Histopathology Index score less than or equal to \[\<=\] 3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0) and endoscopic remission at the participant level.
Time frame: At Week 48
Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48
IBDQ response at Week 48 is defined as an improvement of at least 16 points in the IBDQ total score from baseline at Week 48. IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate disease-specific health related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, AP), systemic function (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.
Time frame: At Week 48
Percentage of Participants with Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Mental Component Summary Score (MCS) Response at Week 48
PROMIS-29 MCS response at Week 48 is defined as an improvement of at least 7 points in PROMIS-29 MCS score from baseline at Week 48. The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities). PROMIS-29 also includes an overall average pain intensity 0-10 numeric rating scale. The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health.
Time frame: At Week 48
Percentage of Participants with Clinical Remission at Week 12
Clinical remission at Week 12 is defined as CDAI score \<150 at Week 12. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame: At Week 12
Percentage of Participants with Endoscopic Response at Week 12
Endoscopic response at Week 12 is defined as greater than (\>) 50 percent (%) improvement from baseline in SES-CD score at Week 12 or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Time frame: At Week 12
Percentage of Participants with Clinical Response at Week 4
Clinical response at week 4 is defined as \>=100-point reduction from baseline in CDAI score at Week 4. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame: At Week 4
Percentage of Participants with Clinical Remission at Week 4
Clinical remission at Week 4 is defined as CDAI score \<150 at Week 4. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame: At Week 4
Number of Participants with Adverse Events (AE) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.
Time frame: Up to approximately 3 years
Who is running it
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- Janssen Research & Development, LLC
- Data monitoring committee
- Yes
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- 78934804CRD3001
- Other IDs
- 2026-525922-39-00
Janssen Research & Development, LLC Clinical Trial
Study director
Janssen Research & Development, LLC
Study sites(287)
Sushruta Multispecialty Hospital and Research Centre
Hubli, India
Recruiting
Asian Institute Of Gastroenterology
Hyderabad, India
Recruiting
S. R. Kalla Memorial General Hospital
Jaipur, India
Recruiting
Lisie Hospital
Kochi, India
Recruiting
P D Hinduja National Hospital and Medical Research Center
Mumbai (ex Bombay), India
Recruiting
Yashoda Super Speciality Hospitals
Secunderabad, India
Recruiting
SIDS (Surat Institute of Digestive Sciences) Hospital and Research Centre
Surat, India
Recruiting
Gujarat Gastro and Vascular Hospital
Surat, India
Recruiting
Mayo Clinic
Scottsdale, Arizona, United States
Recruiting
GIA Sun City
Sun City, Arizona, United States
Recruiting
Clinnova Research
Anaheim, California, United States
Recruiting
Gastro SB Clinic
Chula Vista, California, United States
Recruiting
United Medical Doctors
Los Alamitos, California, United States
Recruiting
Medical Associates Research Group, Inc.
San Diego, California, United States
Recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado, United States
Recruiting
Florida Research Center Inc.
Lakewood Rch, Florida, United States
Recruiting
Sanchez Clinical Research, Inc
Miami, Florida, United States
Recruiting
Endoscopic Research Inc
Orlando, Florida, United States
Recruiting
GCP Clinical Research
Tampa, Florida, United States
Recruiting
Atlanta Gastroenterology Specialists
Suwanee, Georgia, United States
Recruiting
Tri-State Gastroenterology Assoc
Crestview Hills, Kentucky, United States
Recruiting
Gastroenterology Clinic of Acadiana
Lafayette, Louisiana, United States
Recruiting
GIA Metairie
Metairie, Louisiana, United States
Recruiting
GIA Kansas City
Lee's Summit, Missouri, United States
Recruiting
New York Gastroenterology Associates
New York, New York, United States
Recruiting
GIA Rochester
Rochester, New York, United States
Recruiting
University of North Carolina Hospital
Chapel Hill, North Carolina, United States
Recruiting
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio, United States
Recruiting
Digestive Disease Specialists Inc
Oklahoma City, Oklahoma, United States
Recruiting
The Oregon Clinic
Portland, Oregon, United States
Recruiting
Michigan Center of Medical Research
Farmington Hill, Pennsylvania, United States
Recruiting
Palmetto Primary and Specialty Care Physicians, Charleston
Summerville, South Carolina, United States
Recruiting
Gastro One
Cordova, Tennessee, United States
Recruiting
Tyler Research Institute, LLC
Tyler, Texas, United States
Recruiting
GIA Webster
Webster, Texas, United States
Recruiting
GIA Richmond
Richmond, Virginia, United States
Recruiting
GI Alliance Tacoma
Tacoma, Washington, United States
Recruiting
Sanatorio Duarte Quiroz
Córdoba, Argentina
Recruiting
GEDYT
Famailla, Argentina
Recruiting
Globalpsy
La Plata, Argentina
Recruiting
Showing 40 of 287 sites. 285 recruiting, 2 not recruiting and 0 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Source: ClinicalTrials.gov record NCT07577843, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.